Translational Breast Cancer Research Consortium

Translating Science into Progress via innovative, high impact, biologically-driven translational and clinical research. Partnering w/ @BCRFcure & @SusanGKomen

[Translational Breast Cancer Research Consortium @TheTBCRC]

https://t.co/YRtpH3IkZL Our mission is to lessen the burden of breast cancer by using a multidisciplinary approach to discover novel mechanisms of breast cancer pathogenesis and test innovative, basic science-based therapeutic strategies.

[Translational Breast Cancer Research Consortium @TheTBCRC]

#ASCO

[Translational Breast Cancer Research Consortium @TheTBCRC]

So much to learn about #malebreastcancer in the ETHAN study being led by Pablo Leone and @TheTBCRC.
❓What is the most effective systemic treatment for HR+ male breast cancer?
🟢Open and enrolling
#ASCO

[Translational Breast Cancer Research Consortium @TheTBCRC]

#ASCO

[Translational Breast Cancer Research Consortium @TheTBCRC]

@TheTBCRC 070 / CAPELA
🔶Is there a benefit to estrogen inhibition in ER+/HER2- metastatic BC when starting chemotherapy?
➡️Elacestrant +|- Capecitabine
🟢Open and enrolling

[Translational Breast Cancer Research Consortium @TheTBCRC]

#ASCO

[Translational Breast Cancer Research Consortium @TheTBCRC]

@theTBCRC 076 / POLKA
❓Does dual Pol + PARP inhibition enhance outcomes in BRCA deficient breast cancer

[Translational Breast Cancer Research Consortium @TheTBCRC]

@TheTBCRC 058 *enrolling now* anti-androgen treatments in AR+ TNBC

[Yara Abdou, MD, MSCR @YAbdouMD]

Incredibly grateful to @ConquerCancerFd @BCRFcure @GatewayforCR @TheTBCRC for all their support of PREDICT-RD/TBCRC-071 and this important work in MRD and early-stage TNBC.

BIG thanks to @ASCO for highlighting!

#bcsm #ASCO2026 @UNC_Lineberger

[Nicole Casasanta, MD @ncasasanta]

@TheTBCRC 050
♦️phase 1b/2 trial of trastuzumab + niraprib in pretx HER2+ MBC
♦️Combinarion with only 1 grade 3 AEs, no grade 4
♦️ORR 7.3%, DCR 43.9%
♦️CBR 34.1% (CR 1, PR 2, SD 15)
♦️11 pts DCR ≥6 m
@ReasorErica #ASCO2026

[Yara Abdou, MD, MSCR @YAbdouMD]

Promising data from TBCRC-053 (P-RAD) by @guptalabunc @AliceHoMD: short-course pre-op RT + pembro appeared to enhance tumor immune infiltration and early nodal response in node-positive TNBC.

Notably, RT converted 71% of “low TCI” tumors into “high TCI,” with early high TCI associated with higher ypN0 (94%) and pCR (85%) rates. Interesting strategy leveraging RT as an immune primer. #ASCO26 #bcsm @OncoAlert @UNC_Lineberger

[Translational Breast Cancer Research Consortium @TheTBCRC]

Nancy Davidson - so deserving of the Karnofsky Award #ASCO

[Translational Breast Cancer Research Consortium @TheTBCRC]

Dr. @norataranto discussing currently enrolling @TheTBCRC 066, a prospective obs study of T-DXd with 2 novel quantitative assays to better predict therapy response in low/ultralow Her2 mbc. Open at 12 sites nationwide! @AngieDemichele

[Nicole Casasanta, MD @ncasasanta]

📣 @thetbcrc066 QuantifyHER trial
🔹Currently enrolling pts HER2-low MBC tx w/ T-DXd
➡️Eval tissue biopsy with HER2 Quantitative Immunofluorescence
🔹Primary endpoint rwORR, secondary rwPFS
🎯 Help us find improved biomarkers for T-DXd! NCT06551116
@yalepathology @norataranto

[Erica Mayer @elmayermd]

Important presentation by ⁦@AngieDemichele⁩ showing 7 year OS outcomes from PALLAS trial, highlighting importance of capturing and reporting post progression tx! ⁦@ABCSGVienna⁩ ⁦@ALLIANCE_org⁩ ⁦@MichaelGnant⁩ ⁦@DFCI_BreastOnc⁩

[Susan G. Komen @SusanGKomen]

At #SABCS25, @guptalabunc presented the P-RAD trial showing that in node+ HR+/HER2- breast cancer, pre‑op radiation with pembrolizumab + chemo boosted immune activity, which may improve the body's response to eradicate cancer 🩺 @SABCSSanAntonio

[Translational Breast Cancer Research Consortium @TheTBCRC]

@guptalabunc presents at #SABCS25 the results of @TheTBCRC 053 / P-RAD trial that showed pre-operative radiation boosts immune infiltrate in HR+/HER2- breast cancer

[Translational Breast Cancer Research Consortium @TheTBCRC]

@TheTBCRC P-RAD study shows that pre-op radiation can stimulate a local and nodal immune response in HR+/HER2- breast cancer treated with immune checkpoint inhibitors.

[Translational Breast Cancer Research Consortium @TheTBCRC]

Using paired samples from primary & metastatic breast cancer sites from AuroraUS, Dr. @michmer4 showed clinical and PAM50 subtype switching which may have treatment implications. Ongoing work as part of @TheTBCRC ARPA-H EVOLVE study #SABCS25

[Translational Breast Cancer Research Consortium @TheTBCRC]

Dr. @michmer4 presented @TheTBCRC study “Molecular causes of subtype switching in primary and metastatic breast tumor pairs from the AURORA US Project” in the #SABCS25 Poster Spotlight 2

[Translational Breast Cancer Research Consortium @TheTBCRC]

Dr. Garrido-Castro discussed mechanisms of ADC resistance identified from the @TheTBCRC AURORA-US dataset, including novel MED12 LoF mechanism. HER2 loss happened after HER2 ADC, but not TROP2 loss post TROP2 ADC. #SABCS25